Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00YQI
|
|||
| Drug Name |
TRC105
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Angiosarcoma [ICD-11: 2B56] | Phase 3 | [1] | |
| Hemangiosarcoma [ICD-11: 2B56.1] | Phase 3 | [2] | ||
| Fallopian tube cancer [ICD-11: 2C74; ICD-10: C57.0] | Phase 2 | [3] | ||
| Gestational trophoblastic neoplasia [ICD-11: 2F33-2F76] | Phase 2 | [2] | ||
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 2 | [2], [4] | ||
| Macular degeneration [ICD-11: 9B78.3; ICD-10: H35.3] | Phase 2 | [3] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56] | Phase 2 | [3] | ||
| Peritoneal cancer [ICD-11: 2C51.Z] | Phase 2 | [3] | ||
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [4], [5] | ||
| Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64; ICD-9: 189] | Phase 2 | [2], [4] | ||
| Soft tissue sarcoma [ICD-11: 2B57; ICD-9: 171] | Phase 2 | [6] | ||
| Breast cancer [ICD-11: 2C60-2C65] | Phase 1 | [2] | ||
| Lung cancer [ICD-11: 2C25.0] | Phase 1 | [2] | ||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Endoglin CD105 (ENG) | Target Info | Modulator | [7], [8] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02979899) Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (TAPPAS). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT01727089) Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer. U.S. National Institutes of Health. | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 6 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 7 | An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 1;20(23):5918-26. | |||
| REF 8 | Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models.Blood. 2017 May 4;129(18):2526-2536. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.